Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 38

1.

The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis.

Hartz B, Marsh R, Rao K, Henter JI, Jordan M, Filipovich L, Bader P, Beier R, Burkhardt B, Meisel R, Schulz A, Winkler B, Albert MH, Greil J, Karasu G, Woessmann W, Corbaciologlu S, Gruhn B, Holter W, Kühl JS, Lang P, Seidel MG, Veys P, Löfstedt A, Ammann S, Ehl S, Janka G, Müller I, Lehmberg K.

Blood. 2016 Apr 20. pii: blood-2015-12-684498. [Epub ahead of print]

PMID:
27099148
2.

A Reduced-Intensity Conditioning Regimen for Patients with Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell Transplantation.

Nelson AS, Marsh RA, Myers KC, Davies SM, Jodele S, O'Brien TA, Mehta PA.

Biol Blood Marrow Transplant. 2016 May;22(5):884-8. doi: 10.1016/j.bbmt.2016.01.026. Epub 2016 Feb 1.

PMID:
26845033
3.

Cytokine Profile of Engraftment Syndrome in Pediatric Hematopoietic Stem Cell Transplant Recipients.

Khandelwal P, Mellor-Heineke S, Rehman N, Lane A, Smiley K, Villanueva J, Marsh RA, Grimley MS, Davies SM, Filipovich AH.

Biol Blood Marrow Transplant. 2016 Apr;22(4):690-7. doi: 10.1016/j.bbmt.2015.12.016. Epub 2015 Dec 29.

PMID:
26740373
4.

Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT.

Marsh RA, Lane A, Mehta PA, Neumeier L, Jodele S, Davies SM, Filipovich AH.

Blood. 2016 Jan 28;127(4):503-12. doi: 10.1182/blood-2015-07-659672. Epub 2015 Dec 7.

PMID:
26644451
5.

A challenging undertaking: Stem cell transplantation for immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome.

Kucuk ZY, Bleesing JJ, Marsh R, Zhang K, Davies S, Filipovich AH.

J Allergy Clin Immunol. 2016 Mar;137(3):953-955.e4. doi: 10.1016/j.jaci.2015.09.030. Epub 2015 Nov 11. No abstract available.

PMID:
26559324
6.

Accuracy of flow cytometric perforin screening for detecting patients with FHL due to PRF1 mutations.

Abdalgani M, Filipovich AH, Choo S, Zhang K, Gifford C, Villanueva J, Bleesing JJ, Marsh RA.

Blood. 2015 Oct 8;126(15):1858-60. doi: 10.1182/blood-2015-06-648659. No abstract available.

PMID:
26450956
7.

AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.

Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, Zhang Y, Liu Z, Fritz JM, Marsh R, Husami A, Kissell D, Nortman S, Chaturvedi V, Haines H, Young LR, Mo J, Filipovich AH, Bleesing JJ, Mustillo P, Stephens M, Rueda CM, Chougnet CA, Hoebe K, McElwee J, Hughes JD, Karakoc-Aydiner E, Matthews HF, Price S, Su HC, Rao VK, Lenardo MJ, Jordan MB.

Science. 2015 Jul 24;349(6246):436-40. doi: 10.1126/science.aaa1663.

PMID:
26206937
8.

Peripheral Blood CD38 Bright CD8+ Effector Memory T Cells Predict Acute Graft-versus-Host Disease.

Khandelwal P, Lane A, Chaturvedi V, Owsley E, Davies SM, Marmer D, Filipovich AH, Jordan MB, Marsh RA.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1215-22. doi: 10.1016/j.bbmt.2015.04.010. Epub 2015 Apr 13.

PMID:
25881755
9.

Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.

Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P, Chandra S, Jodele S, Myers KC, Grimley M, Dandoy C, El-Bietar J, Kumar AR, Leemhuis T, Zhang K, Bleesing JJ, Jordan MB, Filipovich AH, Davies SM.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1460-70. doi: 10.1016/j.bbmt.2015.04.009. Epub 2015 Apr 10.

10.

Hemophagocytic lymphohistiocytosis in a female patient due to a heterozygous XIAP mutation and skewed X chromosome inactivation.

Holle JR, Marsh RA, Holdcroft AM, Davies SM, Wang L, Zhang K, Jordan MB.

Pediatr Blood Cancer. 2015 Jul;62(7):1288-90. doi: 10.1002/pbc.25483. Epub 2015 Mar 19.

PMID:
25801017
11.

Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases.

Haines HL, Bleesing JJ, Davies SM, Hornung L, Jordan MB, Marsh RA, Filipovich AH.

Biol Blood Marrow Transplant. 2015 Feb;21(2):288-92. doi: 10.1016/j.bbmt.2014.10.010. Epub 2014 Oct 18.

12.

SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma.

Wojton J, Meisen WH, Jacob NK, Thorne AH, Hardcastle J, Denton N, Chu Z, Dmitrieva N, Marsh R, Van Meir EG, Kwon CH, Chakravarti A, Qi X, Kaur B.

Oncotarget. 2014 Oct 30;5(20):9703-9.

13.

An in vitro skin penetration model for compromised skin: estimating penetration of polyethylene glycol [¹⁴C]-PEG-7 phosphate.

Dey S, Rothe H, Page L, O'Connor R, Farahmand S, Toner F, Marsh R, Wehmeyer K, Zhou S.

Skin Pharmacol Physiol. 2015;28(1):12-21. doi: 10.1159/000362284. Epub 2014 Jul 15.

PMID:
25034576
14.

Bortezomib for refractory autoimmunity in pediatrics.

Khandelwal P, Davies SM, Grimley MS, Jordan MB, Curtis BR, Jodele S, Marsh R, Filipovich AJ.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1654-9. doi: 10.1016/j.bbmt.2014.06.032. Epub 2014 Jun 28.

15.

Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.

Marsh RA, Bleesing JJ, Chandrakasan S, Jordan MB, Davies SM, Filipovich AH.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1641-5. doi: 10.1016/j.bbmt.2014.06.003. Epub 2014 Jun 9.

16.

Clinical flow cytometric screening of SAP and XIAP expression accurately identifies patients with SH2D1A and XIAP/BIRC4 mutations.

Gifford CE, Weingartner E, Villanueva J, Johnson J, Zhang K, Filipovich AH, Bleesing JJ, Marsh RA.

Cytometry B Clin Cytom. 2014 Jul;86(4):263-71. doi: 10.1002/cyto.b.21166. Epub 2014 Feb 19.

17.

Clinical Flow Cytometric Screening of SAP and XIAP Expression Accurately Identifies Patients with SH2D1A and XIAP/BIRC4 Mutations.

Gifford CE, Weingartner E, Villanueva J, Johnson J, Zhang K, Filipovich AH, Bleesing JJ, Marsh RA.

Cytometry B Clin Cytom. 2014 Feb 7. doi: 10.1002/cytob.21166. [Epub ahead of print]

18.

The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.

Khandelwal P, Lawrence J, Filipovich AH, Davies SM, Bleesing JJ, Jordan MB, Mehta P, Jodele S, Grimley MS, Kumar A, Myers K, Marsh RA.

Pediatr Transplant. 2014 Feb;18(1):94-102. doi: 10.1111/petr.12183. Epub 2013 Oct 30.

19.

An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.

Marsh RA, Kim MO, Liu C, Bellman D, Hart L, Grimley M, Kumar A, Jodele S, Myers KC, Chandra S, Leemhuis T, Mehta PA, Bleesing JJ, Davies SM, Jordan MB, Filipovich AH.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1625-31. doi: 10.1016/j.bbmt.2013.09.001. Epub 2013 Sep 10.

20.

Elevated Granzyme B in Cytotoxic Lymphocytes is a Signature of Immune Activation in Hemophagocytic Lymphohistiocytosis.

Mellor-Heineke S, Villanueva J, Jordan MB, Marsh R, Zhang K, Bleesing JJ, Filipovich AH, Risma KA.

Front Immunol. 2013 Mar 22;4:72. doi: 10.3389/fimmu.2013.00072. eCollection 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk